Zevra Therapeutics (ZVRA) Total Liabilities (2014 - 2026)

Zevra Therapeutics has reported Total Liabilities for 13 years, with the latest figure at $72.8 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 44.74% year-over-year to $72.8 million; the trailing twelve-month figure through Mar 2026 stood at $72.8 million (down 44.74% YoY), and the FY2025 full-year result was $130.1 million, down 6.06% from the prior year.
• Total Liabilities for Q1 2026 stood at $72.8 million, down from $130.1 million in the prior quarter.
• The five-year high for Total Liabilities was $139.0 million in Q2 2025, with the low at $5.9 million in Q3 2023.
• Historically, Total Liabilities has averaged $78.2 million across 5 years, with a median of $102.5 million in 2024.
• Annual changes were most pronounced in 2023 — Total Liabilities tumbled 85.86% — and 2024, when it soared 1947.43%.
• Zevra Therapeutics' Total Liabilities stood at $40.2 million in 2022, then soared by 174.65% to $110.5 million in 2023, then climbed by 25.35% to $138.5 million in 2024, then slipped by 6.06% to $130.1 million in 2025, then plunged by 44.05% to $72.8 million in 2026.
• The last three Total Liabilities figures came in at $72.8 million (Q1 2026), $130.1 million (Q4 2025), and $137.0 million (Q3 2025), per Business Quant data.